

DAFTAR PUSTAKA

- Assinger, A., Schrottmaier, W., Salzmann, M. & Rayes, J., 2019, "Platelets in Sepsis: An Update on Experimental Models and Clinical Data", *Front Immuno.*, 10, 1687.
- Bağırsakçı, E. et al., 2017, "Role of Albumin in Growth Inhibition in Hepatocellular Carcinoma". *Oncology.*, 93. 2. 136-142.
- Bhogal, H. K. & Sanyal, A. J., 2016, "The molecular pathogenesis of cholestasis in sepsis". *Front Biosci (Elite Ed)*. 5. 87-96.
- Bihari, C., Rastogi, A., Shasthry, S. M., Bajpai, M., Bhadoria, A. S., Rajesh, S., et al, 2016. "Platelets contribute to growth and metastasis in hepatocellular carcinoma". *APMIS : acta pathologica, microbiologica, et immunologica Scandinavica*. 124.9.776–786.
- Božin, T., Mustapić, S., Bokun, T., Patrlj, L., Rakić, M., Aralica, G. et al, 2018. "Albi Score as a Predictor of Survival in Patients with Compensated Cirrhosis Resected for Hepatocellular Carcinoma: Exploratory Evaluation in Relationship to Palbi and Meld Liver Function Scores". *Acta clinica Croatica*, 57, 2, 292–300.
- Bréchet, C., 2004. "Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms". *Gastroenterology* , 127, 5, 56-61.
- Carr, B. I., Guerra, V., Giannini, E. G., Farinati, F., Ciccarese, F., Ludovico Rapaccini, G., et al, 2014. "Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype". *Seminars in oncology*, 41, 2, 252–258.
- Chang, M. H., You, S. L., Chen, C. J., Liu, C. J., Lee, C. M., Lin, S. M., et al, 2009. "Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study". *Journal of the National Cancer Institute*, 101, 19, 1348–1355.
- Couto, O. F., Dvorchik, I. & Carr, B. I., 2007. "Causes of death in patients with unresectable hepatocellular carcinoma". *Digestive diseases and sciences*, 52, 11, pp. 3285-3289.
- D'souza, S., Lau, K. C., Coffin, C. S. & Patel, T. R., 2020. "Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma". *World J Gastroenterol.*, 26, 38, 5759-83.
- Dahlan, S., 2013. *Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan*. Edisi 3 ed. Jakarta: Salemba Medika.
- Dhanasekaran, R., Bandoh, S. & Roberts, L. R., 2016. "Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances". *F1000Research*, 1-15.
- EASL, 2018. "EASL Clinical Practice Guidelines : Management of Hepatocellular carcinoma". *Journal of Hepatology*, 69, 182-236.

- Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., *et al*, 2021. "Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021". *Intensive care medicine*, 47,11, 1181–1247.
- Forner, A., Llovet, J. M. & Bruix, J., 2012. "Hepatocellular carcinoma". *Lancet (London, England)*, 379, 9822, 1245-1255.
- Giannini, E. G., Farinati, F., Ciccarese, F., Pecorelli, A., Rapaccini, G. L., Di Marco, M. *et al*. (2015). "Prognosis of untreated hepatocellular carcinoma". *Hepatology (Baltimore, Md.)*, 61, 1, 184–190.
- Gray, S. H., White, J. A., Li, P., Kilgore, M. L., Redden, D. T., Abdel Aal, A. K., Simpson, H. N., *et al*, 2017. "A SEER Database Analysis of the Survival Advantage of Transarterial Chemoembolization for Hepatocellular Carcinoma: An Underutilized Therapy". *Journal of vascular and interventional radiology : JVIR*, 28, 2, 231–237.
- Gupta, D. & Lis, C. G., 2010. "Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature". *Nutr J*, 9, 69.
- Hansmann, J., Evers, M. J., Bui, J. T., Lokken, R. P., Lipnik, A. J., Gaba, R. C., *et al*, 2017. "Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades Accurately Predict Overall Survival in High-Risk Patients Undergoing Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma". *Journal of vascular and interventional radiology : JVIR*, 28, 9, 1224–1231.
- Hassanipour, S., Vali, M., Gaffari-Fam, S., Nikbakht, H. A., Abdzadeh, E., Joukar, F., *et al*, 2020. "The survival rate of hepatocellular carcinoma in Asian countries: a systematic review and meta-analysis". *EXCLI journal*, 19, 108–130.
- Jaruvongvanich, V., Sempokuya, T. & Wong, L., 2018. "Is there an optimal staging system or liver reserve model that can predict outcome in hepatocellular carcinoma?". *Journal of gastrointestinal oncology*, 9, 4, 750-761.
- Karademir, S., 2018. "Staging of hepatocellular carcinoma Hepatoma Research". *Hepatoma Research*, 4, 58.
- Kemenkes, 2019. Hari Kanker Sedunia - 2019. [Online] Available at: <https://www.kemkes.go.id/article/view/19020100003/hari-kanker-sedunia-2019.html> [Accessed 16 October 2022].
- Keputusan Menteri Kesehatan No. HK.01.07/MENKES/1355/2022, 2022. [kemkes.go.id](https://yankes.kemkes.go.id/unduh/fileunduh/1664864202_179501.pdf). [Online]. Available at: https://yankes.kemkes.go.id/unduh/fileunduh/1664864202_179501.pdf [Accessed 20 8 2023].
- Kong, J. Y., Li, S. M., Fan, H. Y., Zhang, L., Zhao, H. J., & Li, S. M., 2018. "Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma". *Medicine*, 97, 33, 11872.
- Kudo, M., 2018. "Management of Hepatocellular Carcinoma in Japan as a World-Leading Model". *Liver Cancer*, 7, 2, 134-147.
- Kumar, P., Dwarka, A., Zahid, T., Rehaman, H., Bains, T. S., Joseph, S. J. *et al.*, 2021. "Causes of Death in Hepatocellular Carcinoma Patients: A SEER-Based Study". *Research Square*. 1-9.

- Le, Y., Shen, J. X., Zhang, Y. F., He, M. K., Kan, A., Chen, H. L., *et al*, 2019. "Transarterial Chemoembolization related to Good Survival for Selected Patients with advanced Hepatocellular Carcinoma". *Journal of Cancer*, 10, 3, 665–671.
- Lee, S. K., Song, M. J., Kim, S. H. & Park, M., 2019. "Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on Platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grade: A nationwide cohort study". *PloS one*, 14, 5, 1-19.
- Liu, P. H., Hsu, C. Y., Hsia, C. Y., Lee, Y. H., Chiou, Y. Y., Huang, Y. H., *et al*, 2017). "ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era". *Journal of gastroenterology and hepatology*, 32, 4, 879–886.
- Liu, Y. & Liu, L., 2022. "Change in the Epidemiology of Hepatocellular Carcinoma in Asia". *Cancers*, 14, 4473, 1-14.
- Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., *et al*, 2021. "Hepatocellular carcinoma". *Nature reviews. Disease primers*, 7, 1, 1-28.
- Loho, I. M. H. I., Lesmana, C. R., Dewiasty, E. & Gani, R. A., 2016. "Hepatocellular Carcinoma in a Tertiary Referral Hospital in Indonesia: Lack of Improvement of One-Year Survival Rates between 1998-1999 and 2013-2014". *Asian Pacific journal of cancer prevention : APJCP*, 17, 4, 2165-2170.
- Lucas, Z., Pangan, C., Patal, P. & Ong, J., 2009. "The clinical profile of hepatocellular carcinoma patients at the Philippine General Hospital". *Philipp J Intern Med*, 47, 1-9.
- Luo, H. M., Zhao, S. Z., Li, C. & Chen, L. P., 2018. "Preoperative platelet-albumin-bilirubin grades predict the prognosis of patients with hepatitis B virus-related hepatocellular carcinoma after liver resection: A retrospective study". *Medicine (United States)*, 9, 12, 1-6.
- Maithel, S. K., Kneuert, P. J., Kooby, D. A., Scoggins, C. R., Weber, S. M., Martin, R. C., 2nd, *et al*, 2011. "Importance of low preoperative platelet count in selecting patients for resection of hepatocellular carcinoma: a multi-institutional analysis". *Journal of the American College of Surgeons*, 212, 4, 638–650.
- Moore A. H., 2019. "Thrombocytopenia in Cirrhosis: A Review of Pathophysiology and Management Options". *Clinical liver disease*, 14, 5, 183–186.
- Ni, J. Y., Fang, Z. T., An, C., Sun, H. L., Huang, Z. M., Zhang, T. Q., *et al*, 2019. "Comparison of albumin-bilirubin grade, platelet-albumin-bilirubin grade and Child-Turcotte-Pugh class for prediction of survival in patients with large hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation". *International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group*, 36, 1, 841–853.

- Norsa'adah, B. & Nurhazalini-Zayani, C. G. C., 2013. "Epidemiology and Survival of Hepatocellular Carcinoma in North-east Peninsular Malaysia". *Asian Pac J Cancer Prev*, 14, 11, 6955-9.
- Pavlovic, N., Rani, B., Gerwins, P. & Heindryckx, F., 2019. "Platelets as Key Factors in Hepatocellular Carcinoma". *Cancers (Basel)*, 11, 7, 1022.
- PPHI, 2017. *Konsensus Nasional Penatalaksanaan Karsinoma Sel Hati*. 1 ed. Jakarta: PPHI.
- Putra, R. P., Kusuma, I. F. & Handoko, A., 2022. "Predictors Factors of Mortality Hepatocellular Carcinoma Patients RSD dr. Soebandi Jember 2018-2020". *Journal of Agromedicine and Medical Sciences*, 8, 1, 18-24.
- Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., *et al*, 2022. "BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update". *Journal of hepatology*, 76, 3, 681–693.
- Rolston K. V. (2017). "Infections in Cancer Patients with Solid Tumors: A Review". *Infectious disease and therapy*, 6, 1, 69–83.
- Sanjo, A., Satoi, J., Ohnishi, A., Maruno, J., Fukata, M., & Suzuki, N., 2003. "Role of elevated platelet-associated immunoglobulin G and hypersplenism in thrombocytopenia of chronic liver diseases". *Journal of gastroenterology and hepatology*, 18, 6, 638–644.
- Schwarz, R. E. & Smith, D. D., 2008. "Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population". *Am J Surg*, 196, 6, 829-36.
- Shehta, A., Han, H. S., Ahn, S., Yoon, Y. S., Cho, J. Y., & Choi, Y. R., 2016. "Post-resection recurrence of hepatocellular carcinoma in cirrhotic patients: Is thrombocytopenia a risk factor for recurrence?". *Surgical oncology*, 25, 4, 364–369.
- Sithinamsuwan, P., Piratvisuth, T., Tanomkiat, W., Apakupakul, N., & Tongyoo, S., 2000. "Review of 336 patients with hepatocellular carcinoma at Songklanagarind Hospital". *World journal of gastroenterology*, 6, 3, 339–343.
- Somboon, K., Siramolpiwat, S. & Vilaichone, R.-K., 2014. "Epidemiology and survival of hepatocellular carcinoma in the central region of Thailand". *Asian Pac J Cancer Prev*, 15, 8, 3567-70.
- Tanaka, K., Tsuji, K., Matsui, T., Kang, J. H., Sakurai, Y., Kodama, Y., *et al*. 2022. "Potential of PALBI-T score as a prognostic model for hepatocellular carcinoma in alcoholic liver disease". *JGH open : an open access journal of gastroenterology and hepatology*, 6, 1, 36–43.
- Tellapuri, S., Sutphin, P. D., Beg, M. S., Singal, A. G., & Kalva, S. P., 2018. "Staging systems of hepatocellular carcinoma: A review". *Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology*, 37, 6, 481–491.
- Tunissiolli, N. M., Castanhole-Nunes, M. M. U., Biselli-Chicote, P. M., Pavarino, E. C., da Silva, R. F., da Silva, R. C., *et al*, 2017. "Hepatocellular Carcinoma: a

- Comprehensive Review of Biomarkers, Clinical Aspects, and Therapy”. *Asian Pacific journal of cancer prevention : APJCP*, 18, 4, 863–872.
- Vardon-Bouines, F., Ruiz, S., Gratacap, M. P., Garcia, C., Payrastre, B., & Minville, V., 2019. “Platelets Are Critical Key Players in Sepsis”. *International journal of molecular sciences*, 20, 14, 3494.
- Villanueva, A., 2019. “Hepatocellular Carcinoma”. *The New England journal of medicine*, 380, 15, 498-510.
- Wang, Z., Gu, X. & Thrift, A. P., 2019. “Factors associated with favorable survival outcomes for Asians with hepatocellular carcinoma: A sequential matching cohort study”. *PLoS One*, 14, 4.
- WHO, 2020. *Cancer Today - Global Cancer Observatory - IARC*. [Online] Available at: <https://gco.iarc.fr/today/fact-sheets-cancers>
- Wiedermann, C. J., 2021. “Hypoalbuminemia as Surrogate and Culprit of Infections”. *International journal of molecular sciences*, 22, 9, 498-510.
- Yan, J., Li, S. & Li, S., 2014. “The role of the liver in sepsis”. *International reviews of immunology*, 33, 6, 498-510.
- Zembower T. R., (2014). “Epidemiology of infections in cancer patients”. *Cancer treatment and research*, 161, 43–89.
- Zhang, Y. J., Chen, M. S., & Chen, Y., 2021. “Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined With Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma”. *JAMA Netw Open*, 4, 9.